TrialsgrambetaRCTs are beautiful
AHA Scientific Sessions 2026Apresentado seg., 9 de nov. · 08:30 GMT-6LBS.05 Late-breaking Science: New Frontiers in Cardiometabolic Risk ReductionTodos os ensaios Late-Breaking Science →

ATTAIN-OSA

2026

ATTAIN-OSA: A Master Protocol to Investigate Orforglipron Once Daily in Participants Who Have Obstructive Sleep Apnea and Obesity or Overweight

In adults with moderate-to-severe obstructive sleep apnoea and obesity or overweight, with or without positive airway pressure, oral orforglipron reduced the apnoea-hypopnoea index at 52 weeks compared with placebo.

Resultado

Desfecho primário: Change in apnoea-hypopnoea index at 52 weeks

Trial 1: mean AHI change -17.8 with orforglipron vs -4.5 with placebo (difference -13.2; 95% CI -17.7 to -8.7; P < .001) at 52 weeks. Trial 2: -17.3 vs -5.3 (difference -12.0; 95% CI -17.1 to -6.9; P < .001). Of 7 key secondary end points, 6 were statistically significant. The change in PROMIS sleep-related impairment was not. Sleep apnoea-specific hypoxic burden difference -45.9 % min/h (95% CI -63.7 to -28.2) in trial 1 and -43.1 % min/h (95% CI -62.4 to -23.8) in trial 2. Body weight -10.4% vs -2.2% (difference -8.3%; 95% CI -9.8% to -6.7%) in trial 1 and -10.7% vs -1.1% (difference -9.6%; 95% CI -10.9% to -8.2%) in trial 2. Gastrointestinal events occurred in 68.0% vs 37.4% in trial 1 and 70.6% vs 36.6% in trial 2.

Publicação original
Subtema
Weight-loss pharmacotherapy
Desenho
Phase 3 master protocol of two double-blind, placebo-controlled trials (Eli Lilly; 66 sites): once-daily oral orforglipron versus placebo for 52 weeks, one study in patients not using PAP, one in patients continuing PAP
Incluídos
712 doentes
Fonte
Malhotra A, Gottlieb DJ, et al. JAMA. 2026; published online 9 November.doi 10.1001/jama.2026.24080

Discussão e crítica

Two double-blind, placebo-controlled trials show that orforglipron reduced the apnoea-hypopnoea index and hypoxic burden over 52 weeks, both in patients not using positive airway pressure and in those using it. The primary endpoint is a polysomnographic surrogate, and the trials report no cardiovascular or other clinical outcomes, while one key secondary patient-reported measure of sleep-related impairment did not reach significance. Gastrointestinal events occurred in roughly twice as many patients with orforglipron as with placebo, and follow-up is limited to one year. Most participants were men, with 31.4% and 26.9% women in the two trials.